-
Article
Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer
Circulating tumor DNA (ctDNA) sequencing guides therapy decisions but has been studied mostly in small cohorts without sufficient follow-up to determine its influence on overall survival. We prospectively foll...
-
Article
Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers
While 2–4% of lung cancers possess alterations in BRAF, little is known about the immune responsiveness of these tumours.
-
Article
Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration
MET exon 14 alterations are oncogenic drivers of non-small-cell lung cancers (NSCLCs)1. These alterations are associated with increased MET activity and preclinical sensitivity to MET inhibition2. Crizotinib is a...
-
Article
High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
Accurate identification of tumor-derived somatic variants in plasma circulating cell-free DNA (cfDNA) requires understanding of the various biological compartments contributing to the cfDNA pool. We sought to ...
-
Article
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Immune checkpoint inhibitor (ICI) treatments benefit some patients with metastatic cancers, but predictive biomarkers are needed. Findings in selected cancer types suggest that tumor mutational burden (TMB) ma...
-
Article
Erratum: Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nat. Med. 23, 703–713 (2017); published online 08 May 2017; corrected after print 14 June 2017 In the version of this article initially published online, the top value in the y axis of the Kaplan–Meier plots i...
-
Article
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
MSK-IMPACT is a clinical sequencing platform able to detect genomic mutations, copy number alterations and structural variants in a panel of cancer-related genes. This assay is implemented prospectively to inf...
-
Article
Risk of hemoptysis in patients with resected squamous cell and other high-risk lung cancers treated with adjuvant bevacizumab
Bevacizumab improves survival in lung adenocarcinomas. The potential anti-tumor benefit of bevacizumab in squamous cell lung cancers (SQCLCs) is unknown because bevacizumab is contraindicated in patients with ...
-
Article
A phase 2 study of weekly albumin-bound paclitaxel (Abraxane®) given as a two-hour infusion
Paclitaxel is an effective therapy for patients with solid tumors. While the albumin-bound formulation eliminates the hypersensitivity reaction caused by the Cremaphor solvent, significant peripheral neuropath...
